Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Robert Henry

    TitleRecall Faculty
    SchoolUniversity of California, San Diego
    DepartmentMedicine
    Address9500 Gilman Drive #9111G
    CA La Jolla 92093
    vCardDownload vCard

      Collapse Research 
      Collapse Research Activities and Funding
      Epicatechin and derivatives to preserve muscle structure function in diabetes
      NIH/NIDDK R01DK098717Mar 10, 2014 - Dec 31, 2017
      Role: Principal Investigator
      Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin
      NIH/NCCIH R01AT008310Sep 1, 2013 - Aug 31, 2014
      Role: Principal Investigator
      Function of the Myo-adipo Axis in Human Obesity and Type 2 Diabetes
      VA I01CX000635Apr 1, 2012 - Mar 31, 2016
      Role: Principal Investigator
      Role of Glycogen Synthase Kinase 3 In Type 2-Diabetes
      NIH/NIDDK R01DK058291Sep 1, 2001 - Jul 31, 2006
      Role: Principal Investigator
      COMPARATIVE STUDIES OF INTRACELLULAR GLUCOSE METABOLISM
      NIH/NIDDK R29DK038949Sep 30, 1988 - Aug 31, 1994
      Role: Principal Investigator
      General Clinical Research Center
      NIH/NCRR M01RR000827Mar 1, 1974 - Nov 30, 2010
      Role: Co-Investigator

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Formentini L, Ryan AJ, Gálvez-Santisteban M, Carter L, Taub P, Lapek JD, Gonzalez DJ, Villarreal F, Ciaraldi TP, Cuezva JM, Henry R. Mitochondrial H+-ATP synthase in human skeletal muscle: contribution to dyslipidaemia and insulin resistance. Diabetologia. 2017 Aug 02. PMID: 28770317.
        View in: PubMed
      2. Müller-Wieland D, Leiter LA, Cariou B, Letierce A, Colhoun HM, Del Prato S, Henry R, Tinahones FJ, Aurand L, Maroni J, Ray KK, Bujas-Bobanovic M. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. Cardiovasc Diabetol. 2017 May 25; 16(1):70. PMID: 28545518.
        View in: PubMed
      3. Espinoza SE, Wang CP, Tripathy D, Clement SC, Schwenke DC, Banerji MA, Bray GA, Buchanan TA, Henry R, Kitabchi AE, Mudaliar S, Stentz FB, Reaven PD, DeFronzo RA, Musi N. Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance. Age (Dordr). 2016 Dec; 38(5-6):485-493. PMID: 27585671.
        View in: PubMed
      4. Henry R, Klein EJ, Han J, Iqbal N. Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study. Diabetes Technol Ther. 2016 Nov; 18(11):677-686. PMID: 27525540.
        View in: PubMed
      5. Colhoun HM, Ginsberg HN, Robinson JG, Leiter LA, Müller-Wieland D, Henry R, Cariou B, Baccara-Dinet MT, Pordy R, Merlet L, Eckel RH. No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. Eur Heart J. 2016 Jul 26. PMID: 27460890.
        View in: PubMed
      6. Mudaliar S, Alloju S, Henry R. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. Diabetes Care. 2016 Jul; 39(7):1115-22. PMID: 27289124.
        View in: PubMed
      7. Peters AL, Henry R, Thakkar P, Tong C, Alba M. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes. Diabetes Care. 2016 Apr; 39(4):532-8. PMID: 26989182.
        View in: PubMed
      8. Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry R, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, DeFronzo RA. Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW. J Clin Endocrinol Metab. 2016 May; 101(5):2056-62. PMID: 26982008.
        View in: PubMed
      9. Mudaliar S, Polidori D, Zambrowicz B, Henry R. Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside. Diabetes Care. 2015 Dec; 38(12):2344-53. PMID: 26604280.
        View in: PubMed
      10. Morello CM, Christopher ML, Ortega L, Khoan J, Rotunno T, Edelman SV, Henry R, Hirsch JD. Clinical Outcomes Associated With a Collaborative Pharmacist-Endocrinologist Diabetes Intense Medical Management "Tune Up" Clinic in Complex Patients. Ann Pharmacother. 2016 Jan; 50(1):8-16. PMID: 26546580.
        View in: PubMed
      11. Henry R, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes. Diabetes Care. 2015 Dec; 38(12):2258-65. PMID: 26486192.
        View in: PubMed
      12. Ma GS, Lopez-Sanchez I, Aznar N, Kalogriopoulos N, Pedram S, Midde K, Ciaraldi TP, Henry R, Ghosh P. Activation of G proteins by GIV-GEF is a pivot point for insulin resistance and sensitivity. Mol Biol Cell. 2015 Nov 15; 26(23):4209-23. PMID: 26378251.
        View in: PubMed
      13. DeFronzo RA, Ferrannini E, Groop L, Henry R, Herman WH, Holst JJ, Hu FB, Kahn CR, Raz I, Shulman GI, Simonson DC, Testa MA, Weiss R. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015; 1:15019. PMID: 27189025.
        View in: PubMed
      14. Eckel RH, Henry R, Yue P, Dhalla A, Wong P, Jochelson P, Belardinelli L, Skyler JS. Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes. Diabetes Care. 2015 Jul; 38(7):1189-96. PMID: 26049552.
        View in: PubMed
      15. Amir Levy Y, Ciaraldi TP, Mudaliar SR, Phillips SA, Henry R. Excessive secretion of IL-8 by skeletal muscle in type 2 diabetes impairs tube growth: potential role of PI3K and the Tie2 receptor. Am J Physiol Endocrinol Metab. 2015 Jul 1; 309(1):E22-34. PMID: 25944879.
        View in: PubMed
      16. Tripathy D, Cobb JE, Gall W, Adam KP, George T, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry R, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Reaven PD, Musi N, Ferrannini E, DeFronzo RA. A Novel Insulin Resistance Index to Monitor Changes in Insulin Sensitivity and Glucose Tolerance: the ACT NOW Study. J Clin Endocrinol Metab. 2015 May; 100(5):1855-62. PMID: 25603459.
        View in: PubMed
      17. Vacanti NM, Divakaruni AS, Green CR, Parker SJ, Henry R, Ciaraldi TP, Murphy AN, Metallo CM. Regulation of substrate utilization by the mitochondrial pyruvate carrier. Mol Cell. 2014 Nov 6; 56(3):425-35. PMID: 25458843.
        View in: PubMed
      18. Henry R, Rosenstock J, Edelman S, Mudaliar S, Chalamandaris AG, Kasichayanula S, Bogle A, Iqbal N, List J, Griffen SC. Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Diabetes Care. 2015 Mar; 38(3):412-9. PMID: 25271207.
        View in: PubMed
      19. Henry R, Mudaliar S, Ciaraldi TP, Armstrong DA, Burke P, Pettus J, Garhyan P, Choi SL, Jacober SJ, Knadler MP, Lam EC, Prince MJ, Bose N, Porksen N, Sinha VP, Linnebjerg H. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects. Diabetes Care. 2014 Sep; 37(9):2609-15. PMID: 24947791.
        View in: PubMed
      20. Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry R, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE. Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus: The AleCardio Randomized Clinical Trial. JAMA. 2014 Apr 16; 311(15):1515-25. PMID: 24682069.
        View in: PubMed
      21. DePaoli AM, Higgins LS, Henry R, Mantzoros C, Dunn FL. Can a Selective PPAR? Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone? Diabetes Care. 2014 Jul; 37(7):1918-23. PMID: 24722496.
        View in: PubMed
      22. Tripathy D, Clement SC, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Gastaldelli A, Henry R, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, DeFronzo RA. Baseline Adiponectin Levels Do Not Influence the Response to Pioglitazone in ACT NOW. Diabetes Care. 2014 Jun; 37(6):1706-11. PMID: 24705615.
        View in: PubMed
      23. Fonseca VA, Devries JH, Henry R, Donsmark M, Thomsen HF, Plutzky J. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications. 2014 May-Jun; 28(3):399-405. PMID: 24561125.
        View in: PubMed
      24. Henry R, Rosenstock J, Logan D, Alessi T, Luskey K, Baron MA. Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. J Diabetes Complications. 2014 May-Jun; 28(3):393-8. PMID: 24631129.
        View in: PubMed
      25. Mudaliar S, Henry R, Boden G, Smith S, Chalamandaris AG, Duchesne D, Iqbal N, List J. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther. 2014 Mar; 16(3):137-44. PMID: 24237386.
        View in: PubMed
      26. Taub PR, Ramirez-Sanchez I, Ciaraldi TP, Gonzalez-Basurto S, Coral-Vazquez R, Perkins G, Hogan M, Maisel AS, Henry R, Ceballos G, Villarreal F. Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: restorative effects of (-)-epicatechin-rich cocoa. Clin Sci (Lond). 2013 Oct; 125(8):383-9. PMID: 23642227.
        View in: PubMed
      27. Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry R, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, Gastaldelli A. Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care. 2013 Nov; 36(11):3607-12. PMID: 24062330.
        View in: PubMed
      28. Ciaraldi TP, Aroda V, Mudaliar SR, Henry R. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment. Metabolism. 2013 Nov; 62(11):1587-96. PMID: 23958241.
        View in: PubMed
      29. Lincoff AM, Tardif JC, Neal B, Nicholls SJ, Rydén L, Schwartz GG, Malmberg K, Buse JB, Henry R, Wedel H, Weichert A, Cannata R, Grobbee DE. Evaluation of the dual peroxisome proliferator-activated receptor a/? agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. Am Heart J. 2013 Sep; 166(3):429-34. PMID: 24016490.
        View in: PubMed
      30. Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Gastaldelli A, Henry R, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes. 2013 Nov; 62(11):3920-6. PMID: 23863810.
        View in: PubMed
      31. Henry R, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013 Aug; 98(8):3446-53. PMID: 23733372.
        View in: PubMed
      32. Mudaliar S, Henry R, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013 Sep; 145(3):574-82.e1. PMID: 23727264.
        View in: PubMed
      33. Henry R, Chilton R, Garvey WT. New options for the treatment of obesity and type 2 diabetes mellitus (narrative review). J Diabetes Complications. 2013 Sep-Oct; 27(5):508-18. PMID: 23726071.
        View in: PubMed
      34. Meyer LK, Ciaraldi TP, Henry R, Wittgrove AC, Phillips SA. Adipose tissue depot and cell size dependency of adiponectin synthesis and secretion in human obesity. Adipocyte. 2013 Oct 1; 2(4):217-26. PMID: 24052897.
        View in: PubMed
      35. Henry R, Logan D, Alessi T, Baron MA. A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes. Clin Ther. 2013 May; 35(5):634-645.e1. PMID: 23578605.
        View in: PubMed
      36. Divakaruni AS, Wiley SE, Rogers GW, Andreyev AY, Petrosyan S, Loviscach M, Wall EA, Yadava N, Heuck AP, Ferrick DA, Henry R, McDonald WG, Colca JR, Simon MI, Ciaraldi TP, Murphy AN. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci U S A. 2013 Apr 2; 110(14):5422-7. PMID: 23513224.
        View in: PubMed
      37. Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, Farrell K, Rothenberg P, Henry R. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013 Aug; 36(8):2154-61. PMID: 23412078.
        View in: PubMed
      38. Taub PR, Higginbotham E, Henry R. Beneficial and detrimental effects of glycemic control on cardiovascular disease in type 2 diabetes. Curr Cardiol Rep. 2013 Feb; 15(2):332. PMID: 23314689.
        View in: PubMed
      39. He Z, Zhu HH, Bauler TJ, Wang J, Ciaraldi T, Alderson N, Li S, Raquil MA, Ji K, Wang S, Shao J, Henry R, King PD, Feng GS. Nonreceptor tyrosine phosphatase Shp2 promotes adipogenesis through inhibition of p38 MAP kinase. Proc Natl Acad Sci U S A. 2013 Jan 2; 110(1):E79-88. PMID: 23236157.
        View in: PubMed
      40. Saremi A, Schwenke DC, Buchanan TA, Hodis HN, Mack WJ, Banerji M, Bray GA, Clement SC, Henry R, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Tripathy D, DeFronzo RA, Reaven PD. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2013 Feb; 33(2):393-9. PMID: 23175674.
        View in: PubMed
      41. Mudaliar S, Armstrong DA, Mavian AA, O'Connor-Semmes R, Mydlow PK, Ye J, Hussey EK, Nunez DJ, Henry R, Dobbins RL. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes Care. 2012 Nov; 35(11):2198-200. PMID: 23011728.
        View in: PubMed
      42. Kung J, Henry R. Thiazolidinedione safety. Expert Opin Drug Saf. 2012 Jul; 11(4):565-79. PMID: 22616948.
        View in: PubMed
      43. Henry R, Mudaliar S, Kanitra L, Woloschak M, Balena R. Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial. J Clin Endocrinol Metab. 2012 Jul; 97(7):2370-9. PMID: 22539590.
        View in: PubMed
      44. Henry R, Buse JB, Sesti G, Davies MJ, Jensen KH, Brett J, Pratley RE. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program. Endocr Pract. 2011 Nov-Dec; 17(6):906-13. PMID: 22193143.
        View in: PubMed
      45. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry R, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Ratner RE, Williams K, Stentz FB, Musi N, Reaven PD. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011 Mar 24; 364(12):1104-15. PMID: 21428766.
        View in: PubMed
      46. Chun KH, Choi KD, Lee DH, Jung Y, Henry R, Ciaraldi TP, Kim YB. In vivo activation of ROCK1 by insulin is impaired in skeletal muscle of humans with type 2 diabetes. Am J Physiol Endocrinol Metab. 2011 Mar; 300(3):E536-42. PMID: 21189360.
        View in: PubMed
      47. Chao EC, Henry R. SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010 Jul; 9(7):551-9. PMID: 20508640.
        View in: PubMed
      48. Mavian AA, Miller S, Henry R. Managing type 2 diabetes: balancing HbA1c and body weight. Postgrad Med. 2010 May; 122(3):106-17. PMID: 20463420.
        View in: PubMed
      49. Mudaliar S, Henry R. Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. Am J Med. 2010 Mar; 123(3 Suppl):S19-27. PMID: 20206728.
        View in: PubMed
      50. Kulasa KM, Henry R. Pharmacotherapy of hyperglycemia. Expert Opin Pharmacother. 2009 Oct; 10(15):2415-32. PMID: 19743938.
        View in: PubMed
      51. Defronzo RA, Banerji M, Bray GA, Buchanan TA, Clement S, Henry R, Kitabchi AE, Mudaliar S, Musi N, Ratner R, Reaven PD, Schwenke D, Stentz FB, Tripathy D. Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord. 2009; 9:17. PMID: 19640291.
        View in: PubMed
      52. Phillips SA, Kung J, Ciaraldi TP, Choe C, Christiansen L, Mudaliar S, Henry R. Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans. Am J Physiol Endocrinol Metab. 2009 Sep; 297(3):E767-73. PMID: 19622782.
        View in: PubMed
      53. Mudaliar S, Henry R. Incretin therapies: effects beyond glycemic control. Eur J Intern Med. 2009 Jul; 20 Suppl 2:S319-28. PMID: 19580951.
        View in: PubMed
      54. Henry R, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet. 2009 Jul 11; 374(9684):126-35. PMID: 19515415.
        View in: PubMed
      55. Mudaliar S, Henry R. Incretin therapies: effects beyond glycemic control. Am J Med. 2009 Jun; 122(6 Suppl):S25-36. PMID: 19464425.
        View in: PubMed
      56. Mafong DD, Henry R. The role of incretins in cardiovascular control. Curr Hypertens Rep. 2009 Feb; 11(1):18-22. PMID: 19146796.
        View in: PubMed
      57. Aroda VR, Ciaraldi TP, Burke P, Mudaliar S, Clopton P, Phillips S, Chang RJ, Henry R. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2009 Feb; 94(2):469-76. PMID: 18984667.
        View in: PubMed
      58. Ciaraldi TP, Aroda V, Mudaliar S, Chang RJ, Henry R. Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab. 2009 Jan; 94(1):157-63. PMID: 18854391.
        View in: PubMed
      59. Savu MK, Phillips SA, Oh DK, Park K, Gerlan C, Ciaraldi TP, Henry R. Response of adiponectin and its receptors to changes in metabolic state after gastric bypass surgery: dissociation between adipose tissue expression and circulating levels. Surg Obes Relat Dis. 2009 Mar-Apr; 5(2):172-80. PMID: 18996753.
        View in: PubMed
      60. Phillips SA, Ciaraldi TP, Oh DK, Savu MK, Henry R. Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue. Am J Physiol Endocrinol Metab. 2008 Oct; 295(4):E842-50. PMID: 18664597.
        View in: PubMed
      61. Henry R. Evolving concepts of type 2 diabetes management with oral medications: new approaches to an old disease. Curr Med Res Opin. 2008 Aug; 24(8):2189-202. PMID: 18573228.
        View in: PubMed
      62. Mafong DD, Henry R. Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. Curr Atheroscler Rep. 2008 Feb; 10(1):55-60. PMID: 18366986.
        View in: PubMed
      63. Aroda V, Ciaraldi TP, Chang SA, Dahan MH, Chang RJ, Henry R. Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil Steril. 2008 May; 89(5):1200-8. PMID: 17706206.
        View in: PubMed
      64. Ciaraldi TP, Nikoulina SE, Bandukwala RA, Carter L, Henry R. Role of glycogen synthase kinase-3 alpha in insulin action in cultured human skeletal muscle cells. Endocrinology. 2007 Sep; 148(9):4393-9. PMID: 17569761.
        View in: PubMed
      65. Mudaliar S, Henry R. Inhaled insulin in patients with asthma and chronic obstructive pulmonary disease. Diabetes Technol Ther. 2007 Jun; 9 Suppl 1:S83-92. PMID: 17563308.
        View in: PubMed
      66. Oh DK, Ciaraldi T, Henry R. Adiponectin in health and disease. Diabetes Obes Metab. 2007 May; 9(3):282-9. PMID: 17391153.
        View in: PubMed
      67. Riddle MC, Henry R, Poon TH, Zhang B, Mac SM, Holcombe JH, Kim DD, Maggs DG. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev. 2006 Nov-Dec; 22(6):483-91. PMID: 16634116.
        View in: PubMed
      68. Ciaraldi TP, Oh DK, Christiansen L, Nikoulina SE, Kong AP, Baxi S, Mudaliar S, Henry R. Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab. 2006 Nov; 291(5):E891-8. PMID: 16757548.
        View in: PubMed
      69. Fonseca VA, Theuma P, Mudaliar S, Leissinger CA, Clejan S, Henry R. Diabetes treatments have differential effects on nontraditional cardiovascular risk factors. J Diabetes Complications. 2006 Jan-Feb; 20(1):14-20. PMID: 16389162.
        View in: PubMed
      70. Shah M, Adams-Huet B, Bantle JP, Henry R, Griver KA, Raatz SK, Brinkley LJ, Reaven GM, Garg A. Effect of a high-carbohydrate versus a high--cis-monounsaturated fat diet on blood pressure in patients with type 2 diabetes. Diabetes Care. 2005 Nov; 28(11):2607-12. PMID: 16249527.
        View in: PubMed
      71. Phillips SA, Choe CC, Ciaraldi TP, Greenberg AS, Kong AP, Baxi SC, Christiansen L, Mudaliar SR, Henry R. Adipocyte differentiation-related protein in human skeletal muscle: relationship to insulin sensitivity. Obes Res. 2005 Aug; 13(8):1321-9. PMID: 16129713.
        View in: PubMed
      72. Ciaraldi TP, Phillips SA, Carter L, Aroda V, Mudaliar S, Henry R. Effects of the rapid-acting insulin analog glulisine on cultured human skeletal muscle cells: comparisons with insulin and insulin-like growth factor I. J Clin Endocrinol Metab. 2005 Oct; 90(10):5551-8. PMID: 16030168.
        View in: PubMed
      73. Cha BS, Ciaraldi TP, Park KS, Carter L, Mudaliar SR, Henry R. Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARgamma agonists. Am J Physiol Endocrinol Metab. 2005 Jul; 289(1):E151-9. PMID: 15727952.
        View in: PubMed
      74. Buse JB, Henry R, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004 Nov; 27(11):2628-35. PMID: 15504997.
        View in: PubMed
      75. Ciaraldi TP, Mudaliar S, Barzin A, Macievic JA, Edelman SV, Park KS, Henry R. Skeletal muscle GLUT1 transporter protein expression and basal leg glucose uptake are reduced in type 2 diabetes. J Clin Endocrinol Metab. 2005 Jan; 90(1):352-8. PMID: 15483099.
        View in: PubMed
      76. Aroda VR, Savu MK, Henry R. Diabetes and obesity: medical diseases, surgical cure? Curr Diab Rep. 2004 Oct; 4(5):317-8. PMID: 15461894.
        View in: PubMed
      77. Bhalla MA, Chiang A, Epshteyn VA, Kazanegra R, Bhalla V, Clopton P, Krishnaswamy P, Morrison LK, Chiu A, Gardetto N, Mudaliar S, Edelman SV, Henry R, Maisel AS. Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol. 2004 Sep 1; 44(5):1047-52. PMID: 15337217.
        View in: PubMed
      78. Sathyaprakash R, Henry R. Hyperglycemia with antipsychotic treatment. Curr Diab Rep. 2004 Feb; 4(1):41-5. PMID: 14764279.
        View in: PubMed
      79. Grotz VL, Henry R, McGill JB, Prince MJ, Shamoon H, Trout JR, Pi-Sunyer FX. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. J Am Diet Assoc. 2003 Dec; 103(12):1607-12. PMID: 14647086.
        View in: PubMed
      80. Sowell M, Mukhopadhyay N, Cavazzoni P, Carlson C, Mudaliar S, Chinnapongse S, Ray A, Davis T, Breier A, Henry R, Dananberg J. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab. 2003 Dec; 88(12):5875-80. PMID: 14671184.
        View in: PubMed
      81. Henry R, Mudaliar S, Chu N, Kim D, Armstrong D, Davis TT, An B, Reinhardt RR. Young and elderly type 2 diabetic patients inhaling insulin with the AERx insulin diabetes management system: a pharmacokinetic and pharmacodynamic comparison. J Clin Pharmacol. 2003 Nov; 43(11):1228-34. PMID: 14551177.
        View in: PubMed
      82. Mudaliar S, Chang AR, Henry R. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract. 2003 Sep-Oct; 9(5):406-16. PMID: 14583425.
        View in: PubMed
      83. Chandran M, Phillips SA, Ciaraldi T, Henry R. Adiponectin: more than just another fat cell hormone? Diabetes Care. 2003 Aug; 26(8):2442-50. PMID: 12882876.
        View in: PubMed
      84. Mathieu-Costello O, Kong A, Ciaraldi TP, Cui L, Ju Y, Chu N, Kim D, Mudaliar S, Henry R. Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal. Metabolism. 2003 May; 52(5):540-6. PMID: 12759881.
        View in: PubMed
      85. Wilmsen HM, Ciaraldi TP, Carter L, Reehman N, Mudaliar SR, Henry R. Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. Am J Physiol Endocrinol Metab. 2003 Aug; 285(2):E354-62. PMID: 12700163.
        View in: PubMed
      86. Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, Baxi S, Mudaliar SR, Henry R. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes. 2003 Mar; 52(3):667-74. PMID: 12606507.
        View in: PubMed
      87. Henry R, Mudaliar SR, Howland WC, Chu N, Kim D, An B, Reinhardt RR. Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. Diabetes Care. 2003 Mar; 26(3):764-9. PMID: 12610035.
        View in: PubMed
      88. Henry R. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. Clin Ther. 2003; 25 Suppl B:B47-63. PMID: 14553866.
        View in: PubMed
      89. Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman OG, Chandran M, Mudaliar SR, Henry R. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care. 2003 Jan; 26(1):1-8. PMID: 12502651.
        View in: PubMed
      90. Sathyaprakash R, Henry R. Preventing diabetes by treating aspects of the metabolic syndrome. Curr Diab Rep. 2002 Oct; 2(5):416-22. PMID: 12643167.
        View in: PubMed
      91. Mudaliar S, Mohideen P, Deutsch R, Ciaraldi TP, Armstrong D, Kim B, Sha X, Henry R. Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles. Diabetes Care. 2002 Sep; 25(9):1597-602. PMID: 12196433.
        View in: PubMed
      92. Ciaraldi TP, Carter L, Rehman N, Mohideen P, Mudaliar S, Henry R. Insulin and insulin-like growth factor-1 action on human skeletal muscle: preferential effects of insulin-like growth factor-1 in type 2 diabetic subjects. Metabolism. 2002 Sep; 51(9):1171-9. PMID: 12200763.
        View in: PubMed
      93. Nikoulina SE, Ciaraldi TP, Mudaliar S, Carter L, Johnson K, Henry R. Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes. 2002 Jul; 51(7):2190-8. PMID: 12086949.
        View in: PubMed
      94. Ciaraldi TP, Cha BS, Park KS, Carter L, Mudaliar SR, Henry R. Free fatty acid metabolism in human skeletal muscle is regulated by PPARgamma and RXR agonists. Ann N Y Acad Sci. 2002 Jun; 967:66-70. PMID: 12079836.
        View in: PubMed
      95. Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry R, Reaven PD. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 2002 Mar; 25(3):542-9. PMID: 11874944.
        View in: PubMed
      96. Kim YB, Ciaraldi TP, Kong A, Kim D, Chu N, Mohideen P, Mudaliar S, Henry R, Kahn BB. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes. 2002 Feb; 51(2):443-8. PMID: 11812753.
        View in: PubMed
      97. Ciaraldi TP, Kong AP, Chu NV, Kim DD, Baxi S, Loviscach M, Plodkowski R, Reitz R, Caulfield M, Mudaliar S, Henry R. Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes. 2002 Jan; 51(1):30-6. PMID: 11756319.
        View in: PubMed
      98. Ciaraldi TP, Carter L, Nikoulina S, Mudaliar S, McClain DA, Henry R. Glucosamine Regulation of Glucose Metabolism in Cultured Human Skeletal Muscle Cells: Divergent Effects on Glucose Transport/Phosphorylation and Glycogen Synthase in Non-Diabetic and Type 2 Diabetic Subjects1. Endocrinology. 1999 Sep 01; 140(9):3971-3980. PMID: 28200692.
        View in: PubMed
      99. Ciaraldi TP, Carter L, Mudaliar S, Kern PA, Henry R. Effects of Tumor Necrosis Factor-a on Glucose Metabolism in Cultured Human Muscle Cells from Nondiabetic and Type 2 Diabetic Subjects* * This work was supported by funds from the American Diabetes Association, the Whittier Institute for Diabetes Research, Medical Research Service, the Department of Veterans Affairs, and the Veteran Affairs Medical Center-San Diego (to R.R.H.); Grant MO1-RR-00827 from the General Clinical Research Branch, Division of Research Resources, NIH, and the Medical Research Service, Department of Veterans Affairs and Veteran Affairs Medical Center-Little Rock (to P.A.K.); and NIH Grant DK-39176. Endocrinology. 1998 Dec 01; 139(12):4793-4800. PMID: 28204231.
        View in: PubMed